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 In 1978, the distinguished professor of psychology Hans Eysenck delivered a scathing 
critique of what was then a new method, that of meta-analysis, which he described as “an 
exercise in mega-silliness”. Based on a provocative essay by John Ioannidis in this issue of 
the journal1, “mega-silliness” may be an appropriate characterization of what the meta-
analysis literature has become. According to surveys of the PubMed database and other 
empirical evaluations, Ioannidis paints a disturbing picture of the current state of affairs, 
where researchers are producing, in epidemic proportions, systematic reviews and meta-
analyses that are redundant, misleading or serving vested interests. 
 
Ioannidis presents an astounding case of 21 different meta-analyses of statins for atrial 
fibrillation in cardiac surgery published within a period of seven years, with some of these 
having practically identical results1. Moreover, his findings are in line with our recent cross-
sectional study of systematic reviews of biomedical research2. We identified 682 systematic 
reviews indexed in MEDLINE® in a single month (February 2014), which is equivalent to 22 
published per day. The majority of reviews did not consider study risk of biases or other 
reporting biases when drawing conclusions. Quality of reporting was highly variable: at least 
a third of reviews did not report use of a protocol, the search logic for at least one database, 
methods for data extraction and risk of bias assessment, or the funding source of the review. 
In addition, at least a third used statistical methods that are discouraged by leading systematic 
review organizations (e.g. the Cochrane Collaboration, The Agency for Healthcare Research 
and Quality’s (AHRQ) Evidence-based Practice Center program). Most concerning, there 
were generally only modest improvements in reporting over the last 10 years. 
 
Why are so many systematic reviews and meta-analyses being produced? As Ioannidis 
demonstrates, a range of factors are at play here. Decision making bodies have a genuine 
 need to synthesize the ever expanding and conflicting biomedical literature on an ever 
increasing number of treatment options, in order to make evidence-based treatment 
recommendations. Researchers face pressures to publish (or perish) in order to advance their 
career. Journal editors recognize that publishing systematic reviews can help increase their 
impact factor, since they tend to be cited more than other types of studies. Industry 
employees can use the results of meta-analyses as a marketing device for their product. In 
addition, the plethora of biomedical journals provides researchers with many options to 
submit systematic reviews for publication, regardless of whether they are actually needed or 
performed rigorously and reported completely. This problem is likely to increase unless 
efforts are made to stop the growing number of “predatory journals”; businesses that pose as 
legitimate open-access publishers who charge publication fees to authors and in return 
publish anything quickly, with little or no peer review or quality control. 
 
Why does the quality of systematic reviews and meta-analyses remain suboptimal? Despite 
best intentions, quality improvement initiatives have not had their desired impact. For 
example, in 2009, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) Statement was disseminated in leading medical journals to address the problem of 
poor reporting in reviews (http://www.prisma-statement.org/). However, endorsement of the 
guideline by journals is highly variable, with some editors only encouraging its use rather 
than implementing systems to monitor adherence, and many not referring to it at all. This 
may explain why we found only a third of systematic reviews explicitly referred to the use of 
PRISMA to guide reporting2. Further, some systematic reviews are conducted without any 
direct funding (13% in our sample). We do not know whether funded reviews are better 
conducted and reported than non-funded ones. Although it is possible that without specific 
 funding reviewers might be less inclined to adopt rigorous, time-consuming methods to focus 
their energies on funded projects.  
 
Can anything be done to curb the mass production of redundant, misleading and conflicted 
systematic reviews and meta-analyses? We believe a number of strategies have potential. One 
is to make major changes to incentive structures in academia. Currently, academic promotion 
committees tend to weigh the number of publications an investigator has more heavily than 
features such as quality, impact and translational potential3. We suspect that research 
practices would change for the better if academics were rewarded for things like making their 
pre-specified analysis intentions publicly available, publishing articles that are more complete 
and transparent so that others are able to replicate the methods, and making the data and 
statistical analysis code available for reanalysis by independent investigators. This applies not 
just to systematic reviews and meta-analyses, but to all research studies. Policies to enhance 
transparency and reproducibility regarding the availability of data and methods for all 
research articles, which have been initiated by several journals, including The Milbank 
Quarterly, are also likely to improve the credibility of research articles in future.   
 
One way to address the problem of misleading systematic reviews is to better educate 
biomedical researchers on research methodology and research waste4. Systematic reviews 
and meta-analyses are often conducted by authors with varied levels of formal training in 
clinical research methods. Education on these methodologies must become the norm, rather 
than the occasional venture, in all biomedical and public health curricula. Educational 
material should sensitize students to the myriad ways in which bias can be introduced into 
systematic review findings, and how to protect against these biases. Formal training in how to 
use reporting guidelines such as PRISMA should also be mandatory. This will, hopefully, 
 lead to a methodologically savvy scientific workforce, with strong concerns for the 
consequences that wasteful research can have on patient health and health care. Implementing 
these strategies will ultimately help reduce waste and increase the value of research4.  
 
The redundancy of systematic reviews and meta-analyses highlighted by Ioannidis1 could be 
addressed using the model of “living systematic reviews”. In this model, after completing an 
initial systematic review, a research community (comprising of collaborations between 
various players, such as scientists and citizen scientists) would regularly search for, screen, 
and select studies with new results, and if any exist, they would update the systematic review 
and meta-analysis with new data5. Rather than needlessly publishing multiple articles 
summarizing each update of the review, proponents of this model envisage a freely accessible 
website with live reporting of results to inform decision-making. We consider the recent 
extension of this concept to “living cumulative network meta-analyses”, which would allow 
for the simultaneous comparison of multiple interventions, and reduce the need for separate 
living meta-analyses addressing a single pairwise comparison5, an exciting development. By 
abolishing the need for systematic review publications, novel ways to acknowledge 
contributions (other than authorship) would need to be developed, and recognized in the 
academic incentive and reward structure. This approach might have a greater chance of 
gaining momentum if funding bodies supported this model of evidence gathering and 
academic institutions rewarded academics who participated in it.    
 
No one group has prime responsibility for curbing the mass production of poor quality 
research, including systematic reviews and meta-analyses; to succeed, the strategies outlined 
above require enhanced collaboration between methodologists, clinical researchers, academic 
institutions, funding bodies, industry, journals and publishers. A scientific culture that values 
 methodological rigor, research transparency and data sharing over rampant productivity will 
hopefully produce systematic reviews that are necessary and non-duplicative, and that do not 
compromise on quality. As Ioannidis’s essay clearly indicates, maintaining the status quo will 
not bring us closer to better value of research.  
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